- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) locally advanced (unresectable) or metastatic breast cancer
- Meeting Date: March 2025
- Public Summary Document (PSD) November 2024 March 2025 PBAC Meetings - (PDF 2MB)
- Public Summary Document (PSD) November 2024 March 2025 PBAC Meetings - (Word 1.8MB)
Related Public Summary Documents